Gluten sensitivity: new epidemic or new myth? Every major change in our diet carries with it the possibility of unforeseen risks.
The American Journal of Cardiology 114(10):1621 (2014)
Fueled in part by recent best-selling books that warn of the evils of gluten in our diets, a significant proportion of our population is now either avoiding foods that contain gluten or eliminating gluten entirely from their diets, and these numbers continue to grow. The gluten-free trend-and th...
Gluten sensitivity: new epidemic or new myth?
Proceedings (Baylor University. Medical Center) 27(4):377 (2014)
Fueled in part by recent bestselling books that warn of the evils of gluten in our diets, a significant proportion of our population is now either avoiding foods that contain gluten or eliminating gluten entirely from their diets, and these numbers continue to grow. The gluten-free trend-and the...
Time for a 6-minute walk?
Archives of Internal Medicine 172(14):1102 (2012)
Translating current knowledge into dementia prevention.
Alzheimer Disease and Associated Disorders 26(4):295 (2012)
Considerable knowledge has been gained from epidemiologic studies and randomized clinical trials regarding risk factors for dementia, including Alzheimer disease (AD) and vascular dementia (VaD). Most identified risk factors for dementia are similar to vascular disease risk factors for heart dis...
Cholesterol, lipoproteins, and cognitive impairment.
Journal of Clinical Lipidology 3(6):368 (2009)
This article discussed the central role of the deposition of amyloid beta in the pathogenesis of Alzheimer disease. (AD), and the animal data which supports the role of cholesterol on its deposition. The effect of mid-life cholesterol is discussed, and the presence of cardiovascular disease risk...
Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Primary prevention of dementia in Alzheimer's disease: a perspective from prevention research in cardiovascular disease and stroke.
Alzheimer's & Dementia 5(2):149 (2009)
Valsartan combination therapy in the management of hypertension - patient perspectives and clinical utility.
Integrated Blood Pressure Control 2:39 (2009)
The morbidity and mortality benefits of lowering blood pressure (BP) in hypertensive patients are well established, with most individuals requiring multiple agents to achieve BP control. Considering the important role of the renin-angiotensin-aldosterone system (RAAS) in the pathophysiology of h...
Nuts as part of a healthy cardiovascular diet.
Current Atherosclerosis Reports 10(6):529 (2008)
The increasing trend of obesity has been associated with a greater prevalence of type 2 diabetes mellitus and may lead to more vascular disease. Nuts, a rich source of monounsaturated fatty acids and fiber, have been shown to decrease the risk of cardiovascular disease and the risk of developing...
Ranolazine for chronic stable angina.
The Lancet 372(9646):1335 (2008)
Ranolazine is a new and unique antianginal drug that has been approved for the treatment of chronic stable angina pectoris. The drug is administered as a sustained-release formulation. Although the drug's mechanism of action has not been fully elucidated, current thinking is that ranolazine, a s...
Point: Lipoproteins are significant factors in Alzheimer's disease: Dementia is impacted by blood plasma lipoproteins.
Journal of Clinical Lipidology 2(5):391 (2008)
Rebuttal: Lipids and dementia.
Journal of Clinical Lipidology 2(5):397 (2008)
Achieving BP goals with valsartan and HCTZ alone and in combination: pooled analysis of two randomized, double-blind, placebo-controlled studies.
Current Medical Research and Opinion 24(9):2617 (2008)
Most patients with hypertension will require combination therapy to achieve blood pressure (BP) goals, especially the elderly, obese, or those with stage 2 hypertension.
To assess BP response and time to achieve BP goals in a diverse population of hypertensive patients treated with hydrochloroth...
Use of vascular ultrasound in clinical trials to evaluate new cardiovascular therapies.
Journal of the National Medical Association 100(2):222 (2008)
Though progress has been made in the fight against cardiovascular disease (CVD), the increasing global prevalence of cardiovascular (CV) risk factors ensures that CVD rates remain high. In order to reduce CVD incidence, a huge effort has been made to uncover additional targets for therapy and no...
Nutritional and exercise aspects of cognitive impairment.
Journal of Clinical Lipidology 1(4):242 (2007)
According to recent evidence, our aging society is in the early phases of an epidemic of cognitive decline. Accordingly, efforts directed at reducing the risk of Alzheimer's disease and dementia will be an important goal of health care efforts. While there are a paucity of successful treatment o...
Rationale for combination therapy in hypertension management: focus on angiotensin receptor blockers and thiazide diuretics.
Southern Medical Journal 100(4):386 (2007)
Despite recognition that hypertension is a major risk factor for cardiovascular events and mortality, blood pressure control rates remain low in the US population. Reflecting clinical trial results, hypertension management guidelines assert the clinical benefit of achieving current blood pressur...
Geriatrics 61(12):22 (2006)
Approximately one-third of the adult population has hypertension. Large-scale clinical trials have convincingly demonstrated that the treatment of isolated systolic and systolic/diastolic hypertension reduces rates of total mortality, cardiovascular mortality, and stroke in older adults, yet con...
Cardiovascular disease risk factors and cognitive impairment.
The American Journal of Cardiology 97(8):1262 (2006)
The role of cardiovascular disease risk factors in the occurrence and progression of cognitive impairment has been the subject of a significant number of publications but has not achieved widespread recognition among many physicians and educated laymen. It is apparent that the active treatment o...
The clinical implications and management of concomitant hypertension and dyslipidemia.
Postgraduate Medicine 119(2):37 (2006)
Hypertension and dyslipidemia often coexist, increasing the risk of cardiovascular disease. Evidence suggesting that concomitant hypertension and dyslipidemia are compelling candidates for a unified approach to treating cardiovascular risk is reviewed in this article. The authors also discuss im...
Relationship of C-reactive protein, metabolic syndrome and diabetes mellitus: potential role of statins.
Journal of the National Medical Association 97(12):1600 (2005)
Atherosclerosis and the metabolic derangements of insulin resistance, metabolic syndrome and diabetes mellitus are all associated with underlying inflammatory processes. C-reactive protein (CRP), a marker of inflammation, has been shown to be a strong independent predictor of vascular events. It...
The case for medical treatment in chronic stable coronary artery disease.
Archives of Internal Medicine 165(22):2587 (2005)